Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Gynecology

Studies advance knowledge in gynecology research

Study 1: Angiotensin II type 1 receptor is a target for ovarian cancer therapy.

"Angiotensin II is a bioactive peptide of the renin-angiotensin system, acting not only as a vasoconstrictor but also as a growth promoter via angiotensin II type 1 receptors (AT₁ )R). The present study examined AT₁ R expression in human ovarian carcinoma and attempted to determine whether AT₁ R blocker could suppress the tumor progression," scientists in Japan report.

"Expression of AT₁ R, vascular endothelial growth factor (VEGF), and...

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications